{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:25:20Z","timestamp":1774862720340,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["FISR2020IP_00850"],"award-info":[{"award-number":["FISR2020IP_00850"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007131","name":"Texas Tech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejmech.2022.115021","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T02:41:25Z","timestamp":1671072085000},"page":"115021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8473-3321","authenticated-orcid":false,"given":"Santo","family":"Previti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Ettari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Calcaterra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Di Maro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan J.","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ziebuhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Schirmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Cosconati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zappal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.115021_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.115021_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"Coronaviridae study group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2022.115021_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"Study Group of the International Committee on Taxonomy of. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Coronaviridae","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2022.115021_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fpubh.2020.00241","article-title":"Economic consequences of the COVID-19 outbreak: the need for epidemic preparedness","volume":"8","author":"Pak","year":"2020","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejmech.2022.115021_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jech-2021-216690","article-title":"COVID-19 pandemic and its impact on social relationships and health","volume":"76","author":"Long","year":"2022","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.ejmech.2022.115021_bib8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.abn1755","article-title":"COVID-19 vaccination: the road ahead","volume":"375","author":"Altmann","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.115021_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.884121","article-title":"Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study","volume":"10","author":"Flacco","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejmech.2022.115021_bib12","first-page":"894","article-title":"SARS-CoV-2 reinfection and COVID-19 severity. Emerg","volume":"11","author":"Nguyen","year":"2022","journal-title":"Microb. Infect."},{"key":"10.1016\/j.ejmech.2022.115021_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.31083\/j.fbl2702065","article-title":"Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody\/vaccine sensitivity","volume":"27","author":"Pru","year":"2022","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.ejmech.2022.115021_bib14","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.115021_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2021.09.013","article-title":"Antibody titers and protection against a SARS-CoV-2 infection","volume":"84","author":"Dimeglio","year":"2022","journal-title":"J. Infect."},{"key":"10.1016\/j.ejmech.2022.115021_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing antibody titres in SARS-CoV-2 infections","volume":"12","author":"Lau","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.115021_bib17","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.3390\/molecules27082523","article-title":"Advances in the development of SARS-CoV-2 Mpro inhibitors","volume":"27","author":"Agost-Beltran","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.115021_bib18","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/D1MD00066G","article-title":"A review of the latest research on M(pro) targeting SARS-COV inhibitors","volume":"12","author":"Yang","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/1568026620666201207095117","article-title":"An updated review on SARS-CoV-2 main proteinase (M(Pro)): protein structure and small-molecule inhibitors","volume":"21","author":"Sabbah","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/ijms23010259","article-title":"A review of the current landscape of SARS-CoV-2 main protease inhibitors: have we hit the bullseye yet?","volume":"23","author":"Macip","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.115021_bib21","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111779","article-title":"Structural and biochemical analysis of the dual inhibition of MG-132 against SARS-CoV-2 main protease (Mpro\/3CLpro) and human cathepsin-L","volume":"22","author":"Costanzi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.115021_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115021_bib24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.115021_bib25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biom11040607","article-title":"SARS-CoV-2 M(pro): a potential target for peptidomimetics and small-molecule inhibitors","volume":"11","author":"Citarella","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2022.115021_bib26","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1021\/acs.jcim.1c00184","article-title":"Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening","volume":"61","author":"Amendola","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2022.115021_bib27","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1021\/acs.jmedchem.7b00405","article-title":"Development of novel peptide-based Michael acceptors targeting rhodesain and falcipain-2 for the treatment of Neglected Tropical Diseases (NTDs)","volume":"60","author":"Previti","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib28","doi-asserted-by":"crossref","first-page":"10617","DOI":"10.1021\/acs.jmedchem.9b00908","article-title":"Optimization strategy of novel peptide-based Michael acceptors for the treatment of Human African Trypanosomiasis","volume":"62","author":"Ettari","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib29","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cmdc.202000360","article-title":"Peptidyl vinyl ketone irreversible inhibitors of rhodesain: modifications of the P2 fragment","volume":"15","author":"Maiorana","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.115021_bib30","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2174\/1389557515666160509125243","article-title":"The inhibition of cysteine proteases rhodesain and TbCatB: a valuable approach to treat Human African Trypanosomiasis","volume":"16","author":"Ettari","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib31","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1016\/j.bmcl.2016.06.047","article-title":"Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents","volume":"26","author":"Ettari","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.115021_bib32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3109\/14756366.2015.1108972","article-title":"Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors","volume":"31","author":"Ettari","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cmdc.202000158","article-title":"Development of novel benzodiazepine-based peptidomimetics as inhibitors of rhodesain from Trypanosoma brucei rhodesiense","volume":"15","author":"Di Chio","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.115021_bib34","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.115021_bib36","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.115021_bib37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, Telaprevir, and Boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2022.115021_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1021\/acsmedchemlett.2c00084","article-title":"Development of urea bond-containing Michael acceptors as antitrypanosomal agents targeting rhodesain","volume":"13","author":"Previti","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.115021_bib39","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.115021_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115021_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2022.115021_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2022.115021_bib43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2174\/0929867328666210526111318","article-title":"Interfering with host proteases in SARS-CoV-2 entry as a promising therapeutic strategy","volume":"29","author":"Muller","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009013","article-title":"The role of cysteine peptidases in coronavirus cell entry and replication: the therapeutic potential of cathepsin inhibitors","volume":"16","author":"Pislar","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2022.115021_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107587","article-title":"Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients","volume":"213","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.115021_bib46","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1021\/acs.jmedchem.1c01494","article-title":"Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L","volume":"65","author":"Ashhurst","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/acschembio.0c00875","article-title":"A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells","volume":"16","author":"Mellott","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.115021_bib48","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.csbj.2022.05.023","article-title":"Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy","volume":"20","author":"Yang","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2022.115021_bib49","article-title":"MPI8 is potent against SARS-CoV-2 by inhibiting dually and selectively the SARS-CoV-2 main protease and the host cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.115021_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2022.115021_bib51","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/ph15060744","article-title":"Discovery of triple inhibitors of both SARS-CoV-2 proteases and human cathepsin L","volume":"15","author":"Meewan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2022.115021_bib52","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.2174\/0929867328666210810125309","article-title":"Dual inhibition of parasitic targets: a valuable strategy to treat malaria and neglected tropical diseases","volume":"29","author":"Previti","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib53","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","article-title":"Dual inhibitors as a new challenge for cancer multidrug resistance treatment","volume":"26","author":"Stankovic","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105020","article-title":"Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development","volume":"187","author":"Liu","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.115021_bib55","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2174\/156802610790725498","article-title":"Enzyme kinetics and hit validation in fluorimetric protease assays","volume":"10","author":"Ludewig","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib56","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/molecules25092064","article-title":"Naphthoquinones as covalent reversible inhibitors of cysteine proteases-studies on inhibition mechanism and kinetics","volume":"25","author":"Klein","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.115021_bib57","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1016\/j.bmc.2018.07.015","article-title":"Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates","volume":"26","author":"Royo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib58","article-title":"Targeting SARS-CoV-2 proteases for COVID-19 antiviral development","volume":"9","author":"Lv","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acscentsci.1c00910","article-title":"Evaluation of SARS-CoV-2 main protease inhibitors using a novel cell-based assay","volume":"8","author":"Cao","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2022.115021_bib60","series-title":"Coronavirus Drug Discovery","first-page":"293","article-title":"Chapter 16 - nanocarriers as delivery tool for COVID-19 drugs","author":"Padhi","year":"2022"},{"key":"10.1016\/j.ejmech.2022.115021_bib61","article-title":"Recent updates on liposomal formulations for detection, prevention and treatment of coronavirus disease (COVID-19)","author":"Dini Fatini Mohammad Faizal","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2022.115021_bib62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pro.2733","article-title":"Covalent docking using autodock: two-point attractor and flexible side chain methods","volume":"25","author":"Bianco","year":"2016","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2022.115021_bib63","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cmdc.202000548","article-title":"Structure-activity relationships of benzamides and isoindolines designed as SARS-CoV protease inhibitors effective against SARS-CoV-2","volume":"16","author":"Welker","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.115021_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116392","article-title":"SAR of novel benzothiazoles targeting an allosteric pocket of DENV and ZIKV NS2B\/NS3 proteases","volume":"47","author":"Maus","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib66","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.3390\/molecules27123765","article-title":"Development of reduced peptide bond pseudopeptide Michael acceptors for the treatment of Human African Trypanosomiasis","volume":"27","author":"Previti","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.115021_bib67","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1016\/j.bmc.2015.09.029","article-title":"Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation","volume":"23","author":"Ettari","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib68","series-title":"GraFit 6","author":"Leatherbarrow","year":"2007"},{"key":"10.1016\/j.ejmech.2022.115021_bib69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.115021_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.antiviral.2017.12.010","article-title":"Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses","volume":"150","author":"Muller","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.115021_bib71","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.115021_bib72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2022.115021_bib73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2022.115021_bib74","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cpc.2013.12.014","article-title":"Generalized scalable multiple copy algorithms for molecular dynamics simulations in NAMD","volume":"185","author":"Jiang","year":"2014","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.ejmech.2022.115021_bib75","series-title":"Schr\u00f6dinger Release 2022-2: Desmond Molecular Dynamics System","year":"2022"},{"key":"10.1016\/j.ejmech.2022.115021_bib76","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.ejmech.2022.115021_bib77","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/00268979600100761","article-title":"Explicit reversible integrators for extended systems dynamics","volume":"87","author":"Martyna","year":"1996","journal-title":"Mol. Phys."},{"key":"10.1016\/j.ejmech.2022.115021_bib78","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A Gen. Phys."},{"key":"10.1016\/j.ejmech.2022.115021_bib79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"A force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theor. Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422009230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422009230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:47:30Z","timestamp":1759330050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422009230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":75,"alternative-id":["S0223523422009230"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.115021","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.115021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115021"}}